Search results for “streptomycin and buberculosis”

FILTER CLEAR FILTERS

SORT author date relevance


FILTER RECORDS BY


Medical Research Council (1948)
Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. BMJ 2:769-782.

View

Medical Research Council (1948)
Streptomycin treatment of tuberculous meningitis. Lancet 1:582-596.

View

Bignall JR, Crofton J (1949)
Antihistamine drugs in the treatment of nausea and vomiting due to streptomycin. BMJ 1:13-14.

View

Hill AB (1937)
Principles of medical statistics. London: Lancet.

View

Jacobs A, Borthwick WM (1950)
Streptomycin in urinary tuberculosis. Proceedings of the Royal Society of Medicine 43:453-466.

View

Medical Research Council (1944)
Clinical trial of patulin in the common cold. Lancet 2:373-5.

View

Long ER, Ferebee SH (1950)
A controlled investigation of streptomycin treatment in tuberculosis. Public Health Reports 65:1421-1451.

View

Balfour TG (1854)
Quoted in West C. Lectures on the Diseases of Infancy and Childhood. London, Longman, Brown, Green and Longmans, p 600.

View

Netter A (1906)
Efficacité de l’ingestion de chlorure de calcium comme moyen préventif des éruptions consecutives aux injections de sérum [Effect of the ingestion of calcium chloride for preventing eruptions following serum injections]. Séances et Mémoires de la Société de Biologie 58:279-280.

View

Amberson JB, McMahon BT, Pinner M (1931)
A clinical trial of sanocrysin in pulmonary tuberculosis. American Review of Tuberculosis 24:401-435.

View

Cousin M (1905)
Des éruptions consecutives aux injections de sérum antidiphthérique et de leur traitement prophylactique par l’ingestion de clorure de calcium. Thèse pour le Doctorat en médicine. Paris : Jules Rousset, 36-44.

View

Bullowa JGM (1928)
Use of antipneumococcic refined serum in lobar pneumonia: data necessary for a comparison between cases treated with serum and cases not so treated, and the importance of a significant control series of cases. JAMA 90: 1354-1358.

View

Hill AB (1937)
Artificial pneumothorax on statistical trial. Lancet 229: 535-536.

View

Choksy NH (1908)
On recent progress in serum-therapy of plague. BMJ 1:1282-1284.

View

Swedish National Association against Tuberculosis. Therapeutic Trials Committee (1950)
Para-aminosalicylic acid treatment in pulmonary tuberculosis. American Review of Tuberculosis 61:597-612.

View

Cecil RL, Plummer N (1930)
Pneumococcus type I pneumonia - a study of eleven hundred and sixty-one cases, with especial reference to specific therapy. JAMA 95:1547-1553.

View

Wagner-Jauregg J (1931)
Ueber die Infektionsbehandlung der progressiven Paralyse [On infection treatment of progressive paralysis]. Münchener Medizinische Wochenschrift 78:4-7.

View

Show


Crofton J† (2004).
The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Bastian H (2004).
Down and almost out in Scotland: George Orwell, tuberculosis and getting streptomycin in 1948. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Chalmers I (2013).
UK Medical Research Council and multicentre clinical trials: from a damning report to international recognition. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Scadding JW (2017).
John Guyett Scadding’s scepticism and pragmatism in addressing treatment uncertainties in clinical practice. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Bryder L (2010).
The Medical Research Council and clinical trial methodologies before the 1940s: the failure to develop a ‘scientific’ approach. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Toth B (2015).
Why the MRC Therapeutic Trials Committee didn’t introduce controlled clinical trials. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Chalmers I (2010).
Why the 1948 MRC trial of streptomycin used treatment allocation based on random numbers. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Armitage P (2009).
A statistical note on the analysis of the 1948 MRC streptomycin trial. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Bryder L (2014).
The Medical Research Council and treatments for tuberculosis before streptomycin. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Crofton J† (2005).
Marc Daniels (1907-1953), a pioneer in establishing standards for clinical trial methods and reporting. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Chalmers I, Dukan E, Podolsky SH, Davey Smith G (2011).
The advent of fair treatment allocation schedules in clinical trials during the 19th and early 20th centuries. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Crofton J† (2007).
Reginald Bignall (1913-2000). JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Chalmers I, Clarke M (2002).
J Guy Scadding and the move from alternation to randomization. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Scadding JG (2002).
Reflections on my studies of the effects of sulphonamide drugs in bacillary dysentery in Egypt, 1943-1944. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Toth B (2018).
Pioneering controlled trials of treatments for erysipelas and pneumonia in Glasgow, 1936-47. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Chalmers I (2010).
Joseph Asbury Bell and the birth of randomized trials. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Tansey EM (2006).
Philip Montagu D’Arcy Hart (1900-2006). JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Farewell V, Johnson A (2017).
Major Greenwood and clinical trials. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Mann H, Djulbegovic B (2012).
Comparator bias: why comparisons must address genuine uncertainties. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Schulz KF, Chalmers I, Altman DG, Grimes DA, Moher D, Hayes RJ (2018).
‘Allocation concealment’: the evolution and adoption of a methodological term. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Toth B (1998)
Clinical trials in British medicine 1858 – 1948, with special reference to the development of the randomised controlled trial. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Doll R (2003).
Controlled trials testing two or more treatments simultaneously. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Marks HM† (2006).
The Kendrick-Eldering-(Frost) pertussis vaccine field trial. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Diaz M, Neuhauser D (2004).
Lessons from using randomization to assess gold treatment for tuberculosis. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Podolsky SH, Davey Smith G (2011).
Park’s story and Winters’ tale: alternate allocation clinical trials in turn of the Century America. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Pollock JI (2017).
A controlled trial using a factorial design reported in 1946. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Rodeck CH (2004).
Geoffrey William Theobald (1896–1977). JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Wartolowska K, Beard DJ, Carr AJ (2017).
The use of placebos in controlled trials of surgical interventions: a brief history. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Cox DR (2009).
Randomization for concealment. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Hemminki E (2005).
Commentary on an early placebo controlled trial in Finland. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Altman DG (2017).
Donald Mainland: anatomist, educator, thinker, medical statistician, trialist, rheumatologist. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Silverman WA† (2003).
Personal reflections on lessons learned from randomized trials involving newborn infants, 1951 to 1967. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Hampton J (2004).
An early parallel group trial in cardiology. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Zwarenstein M (2016).
‘Pragmatic’ and ‘Explanatory’ attitudes to randomized trials. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Cox-Maksimov D (1997)
The Making of the Clinical Trial in Britain, 1910-1945: Expertise, the State and the Public. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Reid CM (2008).
Donald Darnley Reid (1914-1977). JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Campbell MJ (2012).
Doing clinical trials large enough to achieve adequate reductions in uncertainties about treatment effects. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Farewell V, Johnson A (2011).
The origins of Austin Bradford Hill’s classic textbook of medical statistics. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Garattini S (2018).
Italian controlled trials to assess prevention and treatment of malaria, 1900-1930s. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Crofton J† (2006).
John Crofton (1912-2009). JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Edwards MV (2004)
Control and the therapeutic trial 1918 – 1948. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Bird SM (2014).
The 1959 meeting in Vienna on controlled clinical trials – a methodological landmark. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Pollock JI (2003).
Clifford Wilson (1906-1997) and Martin Pollock (1914-1999). JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Tröhler U (2010).
The introduction of numerical methods to assess the effects of medical interventions during the 18th century: a brief history. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Gartlehner G, Stepper K (2011).
Julius Wagner-Jauregg: pyrotherapy, Simultanmethode, and ‘racial hygiene’. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

1.2 Why treatment comparisons are essential

View

2.2 The need to compare like-with-like in treatment comparisons

View

2.4 The need to avoid differences in the way treatment outcomes are assessed

View

4.1 Improving reports of research

View

Building the Library

View

Diferencias en la manera en que se evalúan los resultados de los tratamientos

View

Diferencias entre las personas comparadas

View

Diferenças entre as pessoas comparadas

View

Diferenças na maneira como os resultados dos tratamentos são avaliados

View

Différences dans la façon dont les résultats des traitements sont évalués

View

Différences entre les personnes comparées

View

Por que as comparações são fundamentais?

View

Por qué son esenciales las comparaciones

View

Pourquoi des comparaisons sont-elles essentielles?

View

Почему важны сравнения

View

Различия в способах оценки результатов лечения

View

Различия между сравниваемыми людьми

View

الاختلافات بين الطريقة التي يجري بها تقيـيم المعالجات

View

الفروق بين الأشخاص الخاضعين للمقارنة

View

مدى أهمية إجراء المقارنات

View

为什么对照必不可少

View

治疗结局评价方式的差异

View

被比较对象之间的差异

View